(ATRC) AtriCure - Ratings and Ratios
Ablation Catheters, Clip Systems, Energy Sources
ATRC EPS (Earnings per Share)
ATRC Revenue
Description: ATRC AtriCure
AtriCure Inc, listed on NASDAQ under the ticker symbol ATRC, operates within the Health Care Equipment sub-industry. The companys market capitalization stands at approximately $1.75 billion, indicating a mid-cap status in the healthcare sector.
To evaluate the companys financial health and potential for future growth, key performance indicators (KPIs) such as revenue growth rate, gross margin, and research and development (R&D) expenditure as a percentage of revenue are crucial. A high R&D spend typically indicates a companys commitment to innovation, which is vital in the healthcare equipment industry where technological advancements drive competitiveness.
The absence of a Price-to-Earnings (P/E) ratio, due to negative earnings, complicates the valuation. However, this is not uncommon for companies in the healthcare sector that are investing heavily in R&D or are in the process of bringing new products to market. Return on Equity (RoE) is negative at -7.88%, suggesting that the company is currently not generating profits from shareholders equity.
Key economic drivers for AtriCure include the demand for minimally invasive surgical procedures, advancements in ablation technologies for treating atrial fibrillation, and the overall growth of the cardiac surgery market. The companys ability to innovate and capture market share in these areas will be critical to its future success.
From a trading perspective, the stocks beta of 1.621 indicates a higher volatility compared to the overall market, suggesting that investors should be prepared for potential price swings. The Average True Range (ATR) of 1.49, or 4.20%, further underscores this volatility, implying that the stock price can fluctuate significantly over short periods.
ATRC Stock Overview
| Market Cap in USD | 1,795m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2005-08-05 |
ATRC Stock Ratings
| Growth Rating | -11.7% |
| Fundamental | 44.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 5.23% |
| Analyst Rating | 4.56 of 5 |
ATRC Dividends
Currently no dividends paidATRC Growth Ratios
| Growth Correlation 3m | 69.6% |
| Growth Correlation 12m | 22.5% |
| Growth Correlation 5y | -77.5% |
| CAGR 5y | -6.66% |
| CAGR/Max DD 3y | -0.10 |
| CAGR/Mean DD 3y | -0.17 |
| Sharpe Ratio 12m | 0.49 |
| Alpha | 0.23 |
| Beta | 0.361 |
| Volatility | 54.25% |
| Current Volume | 337.7k |
| Average Volume 20d | 354.7k |
| Stop Loss | 33.2 (-5.2%) |
| Signal | 1.16 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-36.4m TTM) > 0 and > 6% of Revenue (6% = 30.0m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA 7.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 40.49% (prev 44.57%; Δ -4.08pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 36.4m > Net Income -36.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.94 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (47.6m) change vs 12m ago 1.38% (target <= -2.0% for YES) |
| Gross Margin 74.71% (prev 74.32%; Δ 0.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 82.90% (prev 71.99%; Δ 10.92pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.85 (EBITDA TTM -15.2m / Interest Expense TTM 6.02m) >= 6 (WARN >= 3) |
Altman Z'' -3.38
| (A) 0.33 = (Total Current Assets 271.3m - Total Current Liabilities 68.8m) / Total Assets 608.8m |
| (B) -0.68 = Retained Earnings (Balance) -414.7m / Total Assets 608.8m |
| (C) -0.05 = EBIT TTM -29.2m / Avg Total Assets 603.1m |
| (D) -2.87 = Book Value of Equity -413.9m / Total Liabilities 144.4m |
| Total Rating: -3.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 44.67
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield 0.48% = 0.24 |
| 3. FCF Margin 1.66% = 0.41 |
| 4. Debt/Equity 0.14 = 2.49 |
| 5. Debt/Ebitda -4.27 = -2.50 |
| 6. ROIC - WACC (= -12.74)% = -12.50 |
| 7. RoE -7.88% = -1.31 |
| 8. Rev. Trend 98.68% = 7.40 |
| 9. EPS Trend 48.78% = 2.44 |
What is the price of ATRC shares?
Over the past week, the price has changed by -0.40%, over one month by -1.71%, over three months by +7.39% and over the past year by +24.72%.
Is AtriCure a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ATRC is around 32.67 USD . This means that ATRC is currently overvalued and has a potential downside of -6.68%.
Is ATRC a buy, sell or hold?
- Strong Buy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ATRC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 50 | 42.8% |
| Analysts Target Price | 50 | 42.8% |
| ValueRay Target Price | 36 | 2.8% |
Last update: 2025-09-10 04:32
ATRC Fundamental Data Overview
CCE Cash And Equivalents = 117.8m USD (Cash And Short Term Investments, last quarter)
P/S = 3.5898
P/B = 3.8521
P/EG = -1.18
Beta = 1.624
Revenue TTM = 499.9m USD
EBIT TTM = -29.2m USD
EBITDA TTM = -15.2m USD
Long Term Debt = 61.9m USD (from longTermDebt, last quarter)
Short Term Debt = 2.91m USD (from shortTermDebt, last quarter)
Debt = 64.8m USD (Calculated: Short Term 2.91m + Long Term 61.9m)
Net Debt = -40.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.74b USD (1.79b + Debt 64.8m - CCE 117.8m)
Interest Coverage Ratio = -4.85 (Ebit TTM -29.2m / Interest Expense TTM 6.02m)
FCF Yield = 0.48% (FCF TTM 8.29m / Enterprise Value 1.74b)
FCF Margin = 1.66% (FCF TTM 8.29m / Revenue TTM 499.9m)
Net Margin = -7.27% (Net Income TTM -36.4m / Revenue TTM 499.9m)
Gross Margin = 74.71% ((Revenue TTM 499.9m - Cost of Revenue TTM 126.4m) / Revenue TTM)
Tobins Q-Ratio = -4.21 (set to none) (Enterprise Value 1.74b / Book Value Of Equity -413.9m)
Interest Expense / Debt = 2.30% (Interest Expense 1.49m / Debt 64.8m)
Taxrate = 21.0% (US default)
NOPAT = -29.2m (EBIT -29.2m, no tax applied on loss)
Current Ratio = 3.94 (Total Current Assets 271.3m / Total Current Liabilities 68.8m)
Debt / Equity = 0.14 (Debt 64.8m / last Quarter total Stockholder Equity 464.5m)
Debt / EBITDA = -4.27 (Net Debt -40.5m / EBITDA -15.2m)
Debt / FCF = 7.82 (Debt 64.8m / FCF TTM 8.29m)
Total Stockholder Equity = 461.3m (last 4 quarters mean)
RoA = -5.97% (Net Income -36.4m, Total Assets 608.8m )
RoE = -7.88% (Net Income TTM -36.4m / Total Stockholder Equity 461.3m)
RoCE = -5.59% (Ebit -29.2m / (Equity 461.3m + L.T.Debt 61.9m))
RoIC = -5.58% (NOPAT -29.2m / Invested Capital 523.8m)
WACC = 7.16% (E(1.79b)/V(1.86b) * Re(7.35%)) + (D(64.8m)/V(1.86b) * Rd(2.30%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 99.24 | Cagr: 0.34%
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 73.12% ; FCFE base≈8.29m ; Y1≈6.15m ; Y5≈3.60m
Fair Price DCF = 1.37 (DCF Value 68.2m / Shares Outstanding 49.7m; 5y FCF grow -30.43% → 3.0% )
EPS Correlation: 48.78 | EPS CAGR: 133.2% | SUE: 1.98 | # QB: 3
Revenue Correlation: 98.68 | Revenue CAGR: 19.59% | SUE: N/A | # QB: None
Additional Sources for ATRC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle